Background

- There are many breast cancer survivors due to high incidence and good prognosis.
- Patients have strong interests in life style factors to make prognosis better since it can be changed by themselves (diet, smoking, alcohol, exercise, obesity, etc.).
- Many clinical trials have been conducted for chemo and hormonal therapy, but few studies are available for life style factors and breast cancer prognosis.

Several cohort studies has started in foreign countries.

Objective

- To investigate the effect of life style factors (diet, physical activity), CAM use on the effect of breast cancer prognosis including QOL, we started cohort studies for breast cancer patients.
- The outline of the design for the cohorts is presented in this report.

Review 1: Risk factors for breast cancer occurrence and recurrence

- Risk factors for breast cancer occurrence rate 
  - Age
  - Family history
  - Menopause
  - Menstrual history
  - Reproductive history
  - Hormone therapy
  - Personal history
  - Genetic factors

- Risk factors for breast cancer recurrence rate 
  - Age
  - Family history
  - Menopause
  - Menstrual history
  - Reproductive history
  - Hormone therapy
  - Personal history
  - Genetic factors

Design of our cohort study: Rainbow of KIBOU

- Problem of conducting cohort study
  - Sample size needed with several hundreds to several thousands
  - Confounder information is necessary such as clinical and treatment information
  - Follow-up is necessary to obtain endpoint information

- Collaboration with large scale multi-institution clinical trials
  - Cohort 05, Cohort 06, Cohort 07...

- Problems in collaboration with clinical trials
  - Dependency of subjects registration to clinical trials
  - Difficulty in collecting qualified samples

- Single institution study with sample collections
  - Cohort NCC (National Cancer Center Hospital)

- Participants:
  - Women diagnosed with breast cancer participating in the clinical trials (Cohort 05, 06, 07)
  - Being treated at National Cancer Center Hospital

- Planned sample size: 10,000

- Endpoints:
  - Primary endpoint: disease-free survival
  - Secondary endpoint: overall survival and the health-related QOL

- Exposure information:
  - Common self-administered questionnaire (Cohort 05, 06, 07)
  - Common self-administered questionnaire, sample (blood and tissue), bone density (Cohort NCC)

- Endpoint information & clinical & treatment information:
  - Information from clinical trials (Cohort 05, 06, 07)
  - Information from charts

- Enrollment period: 3 years to 5 years

- Follow-up period: at least 5 years

- Statistical analysis:
  - Association between prognosis and items below
  - Information from the questionnaire
  - Information from blood and tissue sample including genetic polymorphism
  - Significant reduction of recurrences and death in sufficient to deficient group

BREAST CANCER COHORT in JAPAN

Yuri Mizota and Seiichiro Yamamoto

(National Cancer Center, Center for Cancer Control and Information Services)

5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 JAPAN  e-mail: ymizota@ncc.go.jp  (Y Mizota)

Cohort 05: Collaboration with clinical trial 'N-SAS BC05'

- N-SAS BC05: Randomized trial to assess the efficacy of a Further 5 Years of Anastrozole Treatment for Postmenopausal Women

- Conducted by CSPOR: Comprehensive Support Project for Oncology Research

- Enrollment: November 2007 ~

- Current condition (As of October 25, 2010)
  - IRB approved at National Cancer Center and 107 of 122 participating institutions

- Questionnaire delivered to 608 among 639 participants of clinical trial

- Baseline data is obtained from 544 pts (Response rate: 89.5%)

Cohort 06: Collaboration with clinical trial 'N-SAS BC06'

- N-SAS BC06: Randomized Phase III Study of Adjuvant Endocrine-Therapy with or without Chemotherapy for Postmenopausal Breast Cancer Patients who Responded to Neoadjuvant

- Conducted by CSPOR: Comprehensive Support Project for Oncology Research

- Enrollment: May 2008 ~

- Current condition (As of October 25, 2010)
  - IRB approved at National Cancer Center and 105 of 129 participating institutions

- Questionnaire delivered to 250 among 304 participants of clinical trial

- Baseline data is obtained from 230 pts (Response rate: 92.0%)

Cohort 07: Collaboration with clinical trial 'N-SAS BC07'

- N-SAS BC07 (two studies)

  - Evaluation of Trastuzumab without Chemotherapy as a Postoperative Adjuvant Therapy in HER2 Positive Early Breast Cancer Patients: Randomized Controlled Trial

  - Cohort Study to Evaluate the Efficacy and Safety of Postoperative Adjuvant Therapy in HER2 Positive Early Breast Cancer Patients

- Conducted by CSPOR: Comprehensive Support Project for Oncology Research

- Enrollment: October 2009

- Current condition (As of October 25, 2010)
  - IRB approved at National Cancer Center and 59 of 64 participating institutions

- Questionnaire delivered to 26 among 27 participants of clinical trial

- Baseline data is obtained from 24 pts (Response rate: 92.3%)

Cohort NCC

- Being conducted at NCC (National Cancer Center Hospital)

- Exposure information: Common cohort questionnaire and sample (blood and tissue)

- Enrollment: November 2010 ~ (in preparation)

- Current condition (As of October 25, 2010)
  - IRB approved at National Cancer Center

Advantage of Cohort NCC

- Most of the breast cancer pts who get surgery in one institution can be registered

- Association between prognosis and biomarker in blood
  - Endogenous hormone level (estradiol, progesterone, insulin, etc.)
  - Biomarker representing nutrient intake, obesity, physical activity

- Nutrients in blood reflecting metabolism and absorption in body (fat, vitamin, etc.)

- Association between prognosis and genetic polymorphism

- Direct effect of genetic factors (polymorphism, treatment interaction)

- (CYP2D6: possible association with tamoxifen treatment) (CYP3A4: association with inhibitor treatment) (CYP3A5: possible association with anti-estrogen treatment)

- Availability of sample

- Storage for future use / biobank with clinical information

This study was supported by Grants-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan. Disclosure Information: I have no financial relationships to disclose (Y Mizota).